



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

**Public Summary**

<b>Summary for ARTG Entry:</b>	199296	METAGENICS ARTHREX
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Metagenics (Aust) Pty Ltd	
<b>Postal Address</b>	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
<b>ARTG Start Date</b>	11/07/2012	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . METAGENICS ARTHREX**

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	19/05/2020
---------------------	-------------------------	-----------------------	------------

**Permitted Indications**

- Maintain/support connective tissue health
- Aid/assist/helps connective tissue production/formation
- Maintain/support bone health
- Maintain/support bone strength
- Help maintain/support bone mineralisation
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
  - Linked indication - Maintain/support joint mobility/flexibility
  - Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling
  - Linked indication - Decrease/reduce/relieve mild joint pain/soreness
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
- Helps maintain/support joint cartilage health
- Maintain/support joint health
- Decrease/reduce/relieve mild joint pain/soreness in athletes
- Maintain/support muscle strength in elderly individuals

**Indication Requirements**

- Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must only refer to mild joint symptoms.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

**Standard Indications**

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist consult your healthcare practitioner (or words to that effect).

Not to be taken by children under 2 years old (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Contains potassium. If you have kidney disease or are taking heart or blood pressure medicines, consult your doctor or pharmacist before use. Keep out of reach of children.

**Additional Product information**

**Pack Size/Poison information**

Pack Size	Poison Schedule
-----------	-----------------

**Components**

**1 . Formulation 1**

**Dosage Form** Powder, oral

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>borax</b>	<b>1.76 mg/g</b>
Equivalent: boron	200 microgram/g
<b>colecalfiferol</b>	<b>1.6666 microgram/g</b>
<b>colloidal anhydrous silica</b>	<b>2.67 mg/g</b>
<b>dimethyl sulfone</b>	<b>100 mg/g</b>
<b>Gelatin</b>	<b>666.67 mg/g</b>
<b>glucosamine sulfate potassium chloride</b>	<b>133.33 mg/g</b>
Equivalent: glucosamine sulfate	100 mg/g
Equivalent: potassium chloride	32.8 mg/g
<b>phytomenadione</b>	<b>4.67 microgram/g</b>

**Other Ingredients (Excipients)**

Acacia

cocoa powder

dl-alpha-tocopherol

Flavour

maize starch

maltodextrin

medium chain triglycerides

potassium bicarbonate

silicon dioxide

Steviol glycosides

sucrose

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.